Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center
{{output}}
Background: The FDA revised the labels of amiodarone and simvastatin in 2002 to warn of increased risk of rhabdomyolysis, the most severe form of myopathy, when the 2 drugs are taken concomitantly in doses greater than 20 milligr... ...
